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A 57-year-old male was diagnosed with mycobacterium tuberculoma and was treated with isoniazid,
rifampicin, ethambutol, and pyrazinamide. Three weeks after initiation of treatment, he presented with
fever and appetite loss. Chest radiograph showed diffuse micronodular shadows on both lung ﬁelds.
High-resolution chest computed tomography ﬁndings were diffuse parenchymal micronodules in both
lungs, which was consistent with hypersensitivity pneumonia. Because drug-induced pneumonia was
suspected, the antituberculous regimen was discontinued. The symptoms and diffuse micronodular
shadows improved. A drug lymphocyte stimulation test was only positive for isoniazid, so we suspected
that the pneumonia was induced by isoniazid. Rifampicin and ethambutol were reintroduced without
any recurrence of the abnormal shadows. Next, we tried desensitization to isoniazid over a period of two
weeks, which was successful without any adverse events. Although isoniazid-induced pneumonia is
extremely rare, it is important to recognize that isoniazid can cause such an adverse reaction. In addition,
drug desensitization may be useful in drug-induced pneumonia.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Isoniazid (INH) plays an important role in treating mycobacte-
rium tuberculosis. Several drugs can cause drug-induced pneu-
monia, but INH-induced pneumonia is extremely rare. In addition,
desensitization to INH in a patient with INH-induced pneumonia
has not been reported. Here we report the successful desensitiza-
tion to INH in a patient with hypersensitivity pneumonia that was
induced by INH.
2. Case report
The case was a 57-year-old man who presented with abnormal
shadows in the left upper lung ﬁeld on a chest radiograph that was
taken during a routine health examination (Fig. 1-A). He had a
history of dyslipidemia, which was not treated with medications.
Computed tomography (CT) of the chest showed a lung nodule
measuring 28 20mm in the left upper lobe. A transbronchial lung
biopsy was performed, and the nodule specimen consisted of aMedicine, National Hospital
, Joyo, Kyoto 610-0113, Japan.
Ltd. This is an open access article ugranuloma with necrosis. On ZiehleNeelsen stain, the sputum,
bronchial lavage, and nodule specimen were negative. After 6
weeks, the bronchial lavage culture yielded Mycobacterium tuber-
culosis. Therefore, we made the diagnosis of mycobacterium
tuberculoma, and treated the patient with INH (0.3 g/day), rifam-
picin (RFP) (0.45 g/day), ethambutol (EB) (0.75 g/day), and pyr-
azinamide (PZA) (1.2 g/day). Three weeks later, he developed fever,
headache, and appetite loss. On physical examination, body tem-
perature was 39.1 C, blood pressure was 96/64 mmHg, pulse rate
was 112 beats/min, and percutaneous oxygen saturation (SpO2) on
room air was 96%. Chest examination was normal, and no lymph
nodes were palpable. At this time, a chest radiograph showed
diffuse micronodular shadows in both lung ﬁelds (Fig. 1-B) and on
high-resolution CT (HRCT) of the chest there were diffuse
numerous parenchymal micronodules in both lungs such as in
hypersensitivity pneumonia (Fig. 2). He was admitted for further
evaluation. Thewhite blood cell (WBC) count was elevated to 8700/
ml with 67.9% neutrophils, 12.6% lymphocytes, 12.1% monocytes,
6.5% eosinophils, and 0.9% basophils. C-reactive protein and lactate
dehydrogenase (LDH)were also elevated to 10.4mg/dl and 243 IU/l.
Other laboratory data including those for liver function, renal
function, electrolytes, KL-6 (179 U/ml), and surfactant protein-D
(104 ng/ml) were within normal range. Cultures of sputum, urine,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiographs. Before treatment with antituberculous drugs, chest radio-
graph showed an abnormal shadow in the left upper lung ﬁeld (A). On admission,
diffuse micronodular shadows in both lung ﬁelds appeared on the chest radiograph
(B).
Fig. 2. On admission, HRCT of the chest showed diffuse numerous parenchymal micronodules in both lungs such as in hypersensitivity pneumonia. Abbreviations: HRCT, high-
resolution computed tomography.
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monia and stopped the antituberculous drugs, after which his
symptoms and diffuse micronodular shadows on chest radiographFig. 3. Chest radiographs on admission (A), one week after discontinuing the antituberculou
patient was desensitized (C). One week after discontinuing the antituberculous drugs, diffuse
(B). After reintroducing rifampicin, ethambutol, and isoniazid, there was no recurrence of aand HRCT (Figs. 3-B, 4-B) rapidly improvedwithout anymedication,
including corticosteroid. A drug lymphocyte stimulation test (DLST)
on a serum sample was performed. As a result, only INH was pos-
itive with an increase in the [3H]-thymidine uptake by 219%
(normal < 180%), while RFP (112%), EB (90%), and PZA (98%) were
negative. Based on this result, we concluded that the pneumonia
was induced by INH. Ten days after the cessation of the antituber-
culous drugs, the patient was discharged. Two weeks after dis-
continuing the antituberculous drugs, PZA (1.2 g/day) was
reintroduced. Although the abnormal shadows and symptoms did
not return, liver dysfunction developed, and PZA was discontinued
again. Since liver function recovered to normal by only stopping
PZA, RFP (0.45 g/day) was reintroduced one week after dis-
continuing PZA, and EB (0.75 g/day) was reintroduced two weeks
after discontinuing PZA. Next, we attempted desensitization to INH
over a period of two weeks. The regimen for desensitization was asfollows: days 1e3 25 mg/day, days 4e6 50 mg/day, days 7e9
100 mg/day, days 10e12 200 mg/day, and days 13 and 14 300 mg/
day. Desensitization to INH was successful, and RFP, EB, and INHs drugs (B), and after reintroducing rifampicin, ethambutol, and isoniazid to which the
micronodular shadows on chest radiograph rapidly improved without any medication
bnormal shadows on the chest radiograph. (C).
Fig. 4. HRCT of the chest on admission (A), one week after discontinuing the antituberculous drugs (B), and after reintroducing rifampicin, ethambutol, and isoniazid to which the
patient was desensitized (C). One week after discontinuing the antituberculous drugs, the numerous diffuse parenchymal micronodules on HRCT rapidly improved without any
medication (B). After reintroducing rifampicin, ethambutol, and isoniazid, there was no recurrence of the abnormal shadows on HRCT (C). Abbreviations: HRCT, high-resolution
computed tomography.
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recurrence of the abnormal shadows on the chest radiographs and
HRCT (Figs. 3-C, 4-C).
3. Discussion
INH is well known to cause various adverse effects such as fever,
rash, liver dysfunction, and peripheral neuropathy. On the other
hand, INH-induced pneumonia is rare and case reports have been
few [1,2]. It was reported that HRCT ﬁndings for INH-induced
pneumonia were similar to those of eosinophilic pneumonia and
were observed as diffuse patchy ground-glass opacity, interlobular
septal line thickness, centrilobular opacity, and intralobular inter-
stitial thickening [2]. In the present case, the HRCT ﬁndings mainly
consisted of the appearance of diffuse parenchymal micronodules
such as in hypersensitivity pneumonia. Since drug-induced pneu-
monia by the same drug can cause various HRCT patterns, it should
be recognized that a diagnosis of drug-induced pneumonia can be
complicated.
In the present case, we made the diagnosis of INH-induced
pneumonia based on the negative results of the culture, rapid
improvement in symptoms, ﬁndings by chest radiograph and HRCT
after the antituberculous drugs were discontinued, and results of
DLST. The usefulness of the DLST for antituberculous drugs was
controversial [3,4]. However, in this case the DLST was only positive
for INH, and RFP, EB, and PZA could reintroduced without any
recurrence of the abnormal shadows. Therefore, we concluded that
the pneumonia was induced by INH.
The efﬁcacy of desensitization to INH was described previously
[5]. Although the guidelines for providing desensitization therapy
may vary by country or region, desensitization to INH succeeded in
19 of 24 patients (79.2%) according to the regimen recommended
by the Japanese Society for Tuberculosis. However, there has beenno previous report on the desensitization to INH in a patient with
INH-induced pneumonia. Using the regimen recommended by the
Japanese Society for Tuberculosis, we succeeded in desensitization
to INH in a patient with INH-induced pneumonia. Therefore, we
consider that desensitization to INH is useful in the treatment of
INH-induced pneumonia. On the other hand, desensitization ther-
apy is recommended only for isoniazid or rifampicin induced fever
or eruption by Japanese Society for tuberculosis. We must be
watchful for the reappearance of hypersensitivity pneumonia
during the desensitization therapy.
In conclusion, we experienced a case of INH-induced pneu-
monia. Although this adverse event is very rare, clinicians should be
aware of INH-induced pneumoniawhen a new pulmonary inﬁltrate
develops in patients being treated by INH. In addition, our results
raise the possibility that desensitization to INHmay be a useful tool
for reintroducing INH in patients with INH-induced pneumonia.
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